Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05120271 · ClinicalTrials.gov registry record · Phase 1
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
A Phase 1 study of Hepatocellular Carcinoma and Merkel Cell Carcinoma, sponsored by Sotio Biotech.
- Active
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 8
- Study locations
NCT05120271 is a Phase 1 study of Hepatocellular Carcinoma and Merkel Cell Carcinoma that is active but no longer recruiting, run by Sotio Biotech. The registered enrollment target is 7 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT05120271, a Phase 1 study of Hepatocellular Carcinoma and Merkel Cell Carcinoma, is active but no longer recruiting, sponsored by Sotio Biotech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL CAR-GPC3 T Cells
Study Locations (8)
Other
- Beatson Institute for Cancer Research Wolfson Wohl Cancer Research Centre - Glasgow
- University College London Hospitals NHS Foundation Trust - London
- The Royal Marsden NHS Foundation Trust - London
Texas
- Baylor Scott and White Research Institute - Dallas
- University of Texas MD Anderson Cancer Center - Houston
California
- Hoag Hospital Newport Beach - Newport Beach
Washington
- Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location - Seattle
Wisconsin
- Froedtert and Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2042-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05120271
The ClinicalTrials.gov registry entry for NCT05120271 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% lower). The listed sponsor is Sotio Biotech, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which CAR-GPC3 T Cells is the first listed.
NCT05120271 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05120271 about?
NCT05120271 is a clinical study titled "BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors". This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.
What is the current status of trial NCT05120271?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-10-26. Estimated completion is 2042-12.
What conditions does trial NCT05120271 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma of the Lung, Myxoid/Round Cell Liposarcoma.
What interventions are being tested in trial NCT05120271?
The interventions under investigation include: CAR-GPC3 T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05120271?
This trial is sponsored by Sotio Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05120271 being conducted?
This trial has 8 study locations across California, Texas, Washington, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.